Editorial: Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)

Jian-Quan Luo; Yan Shu; Wei Zhang

doi:10.3389/fendo.2023.1287807

Editorial: Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)

Front Endocrinol (Lausanne). 2023 Sep 18:14:1287807. doi: 10.3389/fendo.2023.1287807. eCollection 2023.

Authors

Jian-Quan Luo^{1

2}, Yan Shu³, Wei Zhang^{4

5

6

7}

Affiliations

¹ Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.
² Institute of Clinical Pharmacy, Central South University, Changsha, China.
³ Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD, United States.
⁴ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
⁵ Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, China.
⁶ Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China.
⁷ National Clinical Research Center for Geriatric Disorders, Changsha, China.

No abstract available

Keywords: microbiome; pharmacogenomics; pharmacomicrobiomics; polymorphisms; precision medicine; type 2 diabetes mellitus.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / genetics
Humans
Microbiota*
Pharmacogenetics
Precision Medicine

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China (No. 81703623), the Scientific Foundation of Hunan (No. 2023JJ30772), and the Wu Jieping Medical Foundation (320.6750.2020-04-14).